NO20012017L - Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose - Google Patents

Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose

Info

Publication number
NO20012017L
NO20012017L NO20012017A NO20012017A NO20012017L NO 20012017 L NO20012017 L NO 20012017L NO 20012017 A NO20012017 A NO 20012017A NO 20012017 A NO20012017 A NO 20012017A NO 20012017 L NO20012017 L NO 20012017L
Authority
NO
Norway
Prior art keywords
vegf
gene
protein
prevent restenosis
growth factor
Prior art date
Application number
NO20012017A
Other languages
English (en)
Other versions
NO20012017D0 (no
Inventor
Kari Alitalo
Mikko O Hiltunen
Markku M Jeltsch
Marc G Achen
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Publication of NO20012017D0 publication Critical patent/NO20012017D0/no
Publication of NO20012017L publication Critical patent/NO20012017L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
NO20012017A 1998-10-26 2001-04-24 Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose NO20012017L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
PCT/US1999/024054 WO2000024412A2 (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Publications (2)

Publication Number Publication Date
NO20012017D0 NO20012017D0 (no) 2001-04-24
NO20012017L true NO20012017L (no) 2001-06-26

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012017A NO20012017L (no) 1998-10-26 2001-04-24 Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose

Country Status (12)

Country Link
EP (1) EP1126870B1 (no)
JP (2) JP4769929B2 (no)
CN (1) CN1338943A (no)
AT (1) ATE275417T1 (no)
AU (1) AU768330B2 (no)
CA (1) CA2340593C (no)
DE (1) DE69920031T2 (no)
ES (1) ES2229788T3 (no)
NO (1) NO20012017L (no)
NZ (1) NZ510121A (no)
PT (1) PT1126870E (no)
WO (1) WO2000024412A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6965010B2 (en) 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
ES2327609T3 (es) * 2000-06-01 2009-11-02 University Of North Carolina At Chapel Hill Procedimientos y compuestos para controlar la liberacion de vectores de parvovirus reconbinantes.
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
JP4584537B2 (ja) 2001-01-16 2010-11-24 ヴァスキュラー セラピーズ リミテッド ライアビリティ カンパニー 吸収可能なマトリックス材料および抗増殖薬を含む、血液透析血管アクセス及び他の血管移植片の機能不全を防止又は治療するための移植可能な装置および方法
WO2002083704A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
BR0309676A (pt) * 2002-04-30 2005-02-22 Fit Biotech Oyl Plc Dispositivo médico
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
JPWO2005039556A1 (ja) * 2003-10-29 2007-02-15 紘一 首藤 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
WO2005089822A1 (ja) * 2004-03-18 2005-09-29 Kensuke Egashira 薬剤・遺伝子溶出型ステント
ES2363758T3 (es) 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
CN101563102B (zh) 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
KR20100129295A (ko) 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
DK1749836T3 (da) * 1996-08-23 2009-08-31 Vegenics Ltd Rekombinant vaskulær endothelcellevækstfaktor D
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
EA199900861A1 (ru) * 1997-04-25 2000-06-26 Коллатерал Терапьютикс Усеченные белки, родственные фактору роста эндотелия сосудов

Also Published As

Publication number Publication date
CA2340593C (en) 2012-05-08
JP4769929B2 (ja) 2011-09-07
DE69920031D1 (de) 2004-10-14
NO20012017D0 (no) 2001-04-24
CN1338943A (zh) 2002-03-06
ES2229788T3 (es) 2005-04-16
JP2002528420A (ja) 2002-09-03
EP1126870B1 (en) 2004-09-08
ATE275417T1 (de) 2004-09-15
EP1126870A2 (en) 2001-08-29
AU768330B2 (en) 2003-12-11
DE69920031T2 (de) 2005-09-22
JP2011173874A (ja) 2011-09-08
WO2000024412A3 (en) 2000-08-03
WO2000024412A2 (en) 2000-05-04
NZ510121A (en) 2003-02-28
CA2340593A1 (en) 2000-05-04
PT1126870E (pt) 2005-01-31
AU1314700A (en) 2000-05-15
JP5231587B2 (ja) 2013-07-10

Similar Documents

Publication Publication Date Title
NO20012017L (no) Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose
Opperman et al. TGF‐β1, TGF‐β2, and TGF‐β3 exhibit distinct patterns of expression during cranial suture formation and obliteration in vivo and in vitro
ATE163046T1 (de) Genetische veränderung von endothelzellen
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
Kallassy et al. Patched (ptch)-associated preferential expression of smoothened (smoh) in human basal cell carcinoma of the skin
WO1998049300A3 (en) Truncated vegf-related proteins
EP0974359A3 (en) FSH and FSH variant formulations, products and methods
SE8902532L (sv) Bestaemning av plasmaproteiner
NO881670L (no) Diagnostisk proeve paa inhibitor for plasminogenaktivatorerav vev- og urokinasetype, samt gen som koder for inhibitoren.
AU8267698A (en) Method for coating stents with dna and expression of recombinant genes from dna coated stent in vivo
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
ATE203766T1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
NO20006026L (no) Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
ES2184059T3 (es) Vector retrovirico y su utilizacion en terapia genica.
Guzman et al. Early and sustained medial cell activation after aortocaval fistula creation in mice
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
BG105682A (en) Bone stimulating factor
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
AU2002300880A1 (en) Vascular Endothelial Growth Factor C (VEGF-C) Protein and Gene, Mutants Thereof, and Uses Thereof